Navigation Links
Major funding awarded to improve treatment of drug-resistant tuberculosis and HIV co-infection

July 23, 2010 (BRONX, NY) For the third time in four months, the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) has awarded Albert Einstein College of Medicine of Yeshiva University a research grant aimed at helping people infected with multidrug-resistant tuberculosis (MDR-TB). Taken together, all three NIH grants total $8.57 million.

The latest awardee Neel Gandhi, M.D., assistant professor of medicine and of epidemiology & population health at Einstein received a five-year, $4 million grant for the first-ever prospective study of antiretroviral therapy for people in South Africa who are co-infected with MDR-TB and HIV, the virus that causes AIDS. "Recent studies have shown that Africa is now facing a rising incidence of people infected with MDR-TB as well as HIV, raising concerns of a catastrophic convergence of the two epidemics," said Dr. Gandhi, the study's principal investigator.

According to the Joint United Nations Programme on HIV/AIDS, an estimated 5.7 million people in South Africa are living with HIV and AIDS - the highest prevalence of any country in the world. TB patients co-infected with HIV face an increased risk of developing active TB disease because HIV infection impairs the ability of the immune system to combat TB.

"No one has looked at how best to treat these patients," said Dr. Gandhi. "The goal of our study is to gather evidence that will guide clinical practice and public health policy for MDR-TB/HIV disease worldwide."

The study will examine whether adding antiretroviral therapy (ART) to MDR-TB therapy is helpful for people with MDR-TB/HIV. While ART has markedly improved survival for people with HIV who are infected with drug-susceptible TB, it is not known how well the therapy will work for those infected with drug-resistant TB.

The study will involve 350 patients who live in the Tugela Ferry area of KwaZulu-Natal, South Africa where South African health officials estimate nearly 39 percent of pregnant women are infected with HIV. One hundred and fifty patients co-infected with MDR-TB and HIV will be given ART plus treatment for MDR-TB; their outcomes, as well as adverse events and their adherence to therapy, will be compared with: (a) 50 controls that have MDR TB, but not HIV, and (b) 150 controls that have drug-susceptible TB and HIV co-infection.

The control group patients will all receive TB therapy, and the 150 control patients with drug-susceptible TB and HIV co-infection will also receive ART. All patients will be followed for three years.

South Africa has the highest burden of HIV worldwide and a rapidly expanding MDR-TB epidemic. In South Africa and in other regions, co-infection with MDR-TB and HIV has been associated with exceedingly high mortality − up to 80 percent at one year.

In April, Einstein scientists were awarded a five-year, $3.9 million grant from the NIAID to study how extensively drug-resistant tuberculosis (XDR-TB) is transmitted in rural South Africa. "The findings could alter public health approaches for controlling the XDR-TB epidemic in the developing world," said principal investigator Sarita Shah, M.D., M.P.H., assistant professor of medicine and of epidemiology & population health.

In May, James Brust, M.D., assistant professor of medicine, received a five-year, $665,000 NIAID Career Development Award to evaluate a novel, home-based treatment program he developed for patients co-infected with HIV and MDR-TB in rural South Africa. Until recently, MDR-TB was treated at centralized TB referral hospitals, with patients admitted for six months of treatment. However, with growing numbers of MDR-TB patients and limited healthcare infrastructure, this centralized approach is no longer working.


Contact: Deirdre Branley
Albert Einstein College of Medicine

Related medicine news :

1. One Month after Major Quake, Ongoing Crises for Haitian Children
2. Virginia House Majority Leader Morgan Griffith Sponsors Legislation Enabling Mobile Solution for Health Care SALEM, Va.
3. Major milestone achieved by our joint venture in China
4. Sunquest Announces Major Software Updates and Enhancements
5. MIT China joint venture is preparing a major commercial launch in July 2010
6. Majority of Americans Approve of President Obamas Handling of Afghanistan and National Security But Disapprove of Handling of Economic Issues, Per Franklin & Marshall College Poll With Hearst Television
7. Highlights of major physics conference in Washington, D.C.
8. The Icebox of Atlanta Selected as T-shirt Vendor for 3 Major Divisions of American Cancer Society's Relay For Life
9. Majority of Marylanders without advance medical directives
10. Pew Report Finds Majority of States Fail to Ensure Proper Dental Health & Access to Care for Children
11. Americans Remain Split on Stalled Health Care Legislation, but Some Provisions Popular Among Majorities of Democrats, Independents and Republicans
Post Your Comments:
(Date:10/13/2017)... ... 13, 2017 , ... The American Board of Family Medicine's (ABFM) Board of ... Executive Officer, succeeding Dr. James C. Puffer upon his retirement. Dr. Newton will serve ... Puffer’s retirement at the end of 2018. Upon assuming the role of President and ...
(Date:10/13/2017)... ... ... Lori R. Somekh, founder of the Law Office of Somekh & ... and special needs planning attorneys. “Membership in ElderCounsel helps our office remain up to ... with elder law attorneys nationwide,” said Somekh. , ElderCounsel was founded ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network ... advocate for action towards gender equality at their inaugural Summit in New York City ... and reached a social audience of over 3 million. To watch the Mobilize Women ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... DevOps and Agile Software Development, has been awarded a contract by the Center ... Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in ...
(Date:10/12/2017)... ... 12, 2017 , ... CitiDent and San Francisco dentists, Dr. ... Oventus O2Vent technology. As many as 18 million Americans are estimated to suffer ... Oral appliances can offer significant relief to about 75 percent of people with ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... , Sept. 28, 2017 Hill-Rom Holdings, Inc. ... earnings conference call and webcast on Friday, November 3, ... (EDT) and ending at approximately 8:30 a.m. (CDT) / ... the company,s 2017 financial performance and guidance for 2018, ... initiatives to enhance operational performance, and long-range financial outlook ...
(Date:9/25/2017)... Sept. 25, 2017  EpiVax, Inc., a leader ... and immune-engineering today announced the launch of EpiVax ... of personalized therapeutic cancer vaccines. EpiVax has provided ... access to enabling technologies to the new precision ... lead EpiVax Oncology as Chief Executive Officer. Gad ...
(Date:9/19/2017)... 2017   ZirMed Inc ., a recognized leader in ... it has been ranked #1 by its users for the ... 2017 User Survey. ZirMed was recognized as the top-ranked end-to-end ... medical centers over 200 beds and holds one of the ... survey history. ...
Breaking Medicine Technology: